Ray Snyder

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Michel Marty, Francesco Cognetti, D Maraninchi et al. · IRIS UNIMORE (University of Modena and Reggio Emilia) · 2005 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

M Marty, Francesco Cognetti, D Maraninchi et al. · Journal of Clinical Oncology · 2005 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: first results of International Breast Cancer Study Group Trial 13–93

M. Colleoni, Shari Gelber, Ray Snyder et al. · Journal of Clinical Oncology · 2004 · 19 citations

Medicine, Oncology, Breast Oncology +4

Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer

Jean-Marc Extra, F. Cognetti, D Maraninchi et al. · Journal of Clinical Oncology · 2005 · 12 citations

Medicine, Oncology, Pharmacology +15